Aristomenis G. Alevizopoulos

Dr. Aristomenis G. Alevizopoulos

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Psychiatriki
Verified
Journal Article
Closed access
AAAristomenis G. Alevizopoulos
Aristomenis G. Alevizopoulos
JKJacob Kritikos
Jacob Kritikos
GAGeorgios Alevizopoulos
Georgios Alevizopoulos
The idea of a network of small devices that would be able to connect each other, appeared in the early 80s. In a prophetic article, Mark Weiser,1 described such a connection, that it is now known under the term of Internet of Things (IoT). In a broadest sense, the term IoT encompasses everything connected to the internet, but it is increasingly being used to define objects that "talk" to each other, creating a network from simple sensors to smartphones and wearables connected. During the recent years this network of communicating devices has been combined with other technological achievements, and particularly with the Virtual Reality (VR)2 and the Artificial Intelligence (AI).3 The emerge of COVID-19 pandemic in 2019, resulted to the poor response and healthcare failures of many countries globally.4 One of the main reasons for such a failure, was the inability of accurate data collection from different sources. Apparently, it was the first time, humanity realized the need for massive amounts of heterogeneous data to be collected, interpreted, and shared. Amid the ongoing COVID-19 pandemic, several innovators and public authorities are looking to leverage IoT tools to reduce the burden on the healthcare systems.5 Mental health is one of the areas that seems to benefit the most of such technologies. A significant decrease of the total amount of ER visits and a dramatic increase of internet access from the patients and care givers along to the development of applications for mental health issues, followed the outbreak of SARS-CoV-2.6 Such technologies proved to be efficient to help mentally ill patients and pioneer the path in the future. Probably the most obvious use of these emerged technologies is the improvement of the telehealth options. Patients who suffer from mental illness face significant problems towards the continuity of care during the crisis.7 Nonetheless, they usually have other health problems, that deprive them from an equitable health care provision. Improved telehealth platforms can give them a single point access to address all their problems. The use of electronic health records can reduce the fragmentary health services and improve the outcome.8 However, this is only the beginning. The COVID-19 crisis and the subsequent social isolation, to reduce both the contamination and the spread of the disease, highlighted the necessity for providing accurate and secure diagnoses and treatments from a safe distance. Virtual reality combined with IoT and AI technologies seem to be a reliable alternative to the classic physical and mental examination and treatment in many areas of mental and neurological diseases.2 These novel techniques can spot the early signs and detect mental illnesses with high accuracy. However, caution and more work are required to bridge the space between these recently thrived technologies and mental health care.7 It is worth mentioning, that internet-oriented health care procedures can also help to reduce the gaps caused by the stigma of mental illness. For example, the development of AI chatbots (an application used to chat directly with a human) can alleviate the fears of judgment of the help seeking persons and provide the professionals with a supplemental support toward improved services to their patients.9 A final remark for conclusion. Humanity is more and more depended to the "intelligent" machines. However, we must not forget that we humans are responsible to set the rules of such co-existence.

9 June 2023 in Virtual Worlds
Verified
Journal Article
Open access
PDF file
Iakovos KritikosIakovos Kritikos
Iakovos Kritikos
AMAlexandros Makrypidis
Alexandros Makrypidis
AAAristomenis G. Alevizopoulos
Aristomenis G. Alevizopoulos
GAGeorgios Ar. Alevizopoulos
Georgios Ar. Alevizopoulos
Dimitris Dionissios KoutsourisDimitris Dionissios Koutsouris
Dimitris Dionissios Koutsouris
Brain–Machine Interfaces (BMIs) have made significant progress in recent years; however, there are still several application areas in which improvement is needed, including the accurate prediction of body movement during Virtual Reality (VR) simulations. To achieve a high level of immersion in VR sessions, it is important to have bidirectional interaction, which is typically achieved through the use of movement-tracking devices, such as controllers and body sensors. However, it may be possible to eliminate the need for these external tracking devices by directly acquiring movement information from the motor cortex via electroencephalography (EEG) recordings. This could potentially lead to more seamless and immersive VR experiences. There have been numerous studies that have investigated EEG recordings during movement. While the majority of these studies have focused on movement prediction based on brain signals, a smaller number of them have focused on how to utilize them during VR simulations. This suggests that there is still a need for further research in this area in order to fully understand the potential for using EEG to predict movement in VR simulations. We propose two neural network decoders designed to predict pre-arm-movement and during-arm-movement behavior based on brain activity recorded during the execution of VR simulation tasks in this research. For both decoders, we employ a Long Short-Term Memory model. The study’s findings are highly encouraging, lending credence to the premise that this technology has the ability to replace external tracking devices.

10 September 2024 in Frontiers in Psychiatry
Verified
Journal Article
Open access
PDF file
GAGeorgios Ar. Alevizopoulos
Georgios Ar. Alevizopoulos
AIArtemis Igoumenou
Artemis Igoumenou
IVIoanna Vardakou
Ioanna Vardakou
AAAristomenis G. Alevizopoulos
Aristomenis G. Alevizopoulos


22 September 2026 in Therapeutic Advances in Psychopharmacology
Verified
Journal Article
Open access
AAAristomenis G. Alevizopoulos
Aristomenis G. Alevizopoulos
VVVasileios Vasilakos
Vasileios Vasilakos
Iakovos KritikosIakovos Kritikos
Iakovos Kritikos
MAMaria Alevizopoulou
Maria Alevizopoulou
EKEleni Korompoki
Eleni Korompoki
SPStavroula A. Paschou
Stavroula A. Paschou
Background: Alcohol use disorder (AUD) affects millions worldwide, but current treatments, such as disulfiram, naltrexone, acamprosate, and topiramate, have limitations in efficacy and tolerability. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), commonly used for diabetes and obesity, may offer a new approach by targeting brain pathways involved in alcohol cravings. Objectives: This review aims to systematically evaluate the preliminary efficacy and safety of GLP-1 RAs and other incretin-based therapies in treating AUD within a recent comparative context, alongside standard pharmacotherapies. Design: Systematic review. Data sources and methods: A comprehensive literature review was conducted by searching the PubMed/Medline, Web of Science, and Scopus databases from February through June 2025. The studies included were either randomized controlled trials (RCTs) or observational studies, written in English. Studies were selected based on their evaluation of GLP-1 RAs or comparator drugs in reducing alcohol consumption or related outcomes in patients with AUD. Results: The selected 12 studies correspond to a population of 95,004 participants, but only 663 were from RCTs, while the majority were from a single registry cohort. Emerging data suggest GLP-1 RAs may reduce heavy drinking days, particularly in individuals with a higher BMI. Furthermore, observational analyses indicate a potential association between GLP-1 RA use and reduced alcohol-related hospitalizations, while metabolic data suggest biologically plausible, albeit unconfirmed, hepatoprotective effects. Conclusion: While the large, aggregated sample size highlights the therapeutic promise of GLP-1 RAs for AUD, particularly for patients with metabolic comorbidities, the heavy reliance on observational data precludes claims of clinical equivalence with established pharmacotherapies. Appropriately powered, dedicated RCTs are required to confirm direct efficacy and long-term safety. Trial registration: Not registered.

20 April 2026 in International Journal of Advanced Multidisciplinary Research and Studies
Verified
Journal Article
Open access
PDF file
AAAristomenis G. Alevizopoulos
Aristomenis G. Alevizopoulos
STStergiou T
Stergiou T
DDDiamantopoulou D
Diamantopoulou D
KIKritikos I
Kritikos I
AGAlevizopoulos G
Alevizopoulos G
In violent scenarios, whether real or fictional, some actions serve as decisive “escalating moves” that terminate the confrontation, in contrast to non-terminal acts that merely incapacitate the opponent. This study outlines the development and initial validation of a questionnaire designed to assess how individuals perceive such escalation moves. Following established scale-development procedures, a conceptual framework was created, items were generated, content validity was evaluated by experts, and a pilot test was conducted with 20 participants. The final 13-item scale demonstrated good internal consistency (McDonald’s ω = .82). The instrument offers a reliable tool for media psychology, aggression research, and studies of public attitudes toward violence.